Drug Type Prophylactic vaccine, Multivalent vaccine |
Synonyms Chimeric Yellow Fever Dengue Virus Serotype 1 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 2 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 3 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 4 (Live, Attenuated), ChimeriVax, ChimeriVax Tetravalent Dengue Vaccine + [13] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Australia (20 Jul 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dengue | Australia | 20 Jul 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Human Papillomavirus Infection | Phase 3 | Malaysia | 01 Dec 2016 | |
Yellow Fever | Phase 3 | Colombia | 07 Sep 2011 | |
Yellow Fever | Phase 3 | Peru | 07 Sep 2011 | |
Severe Dengue | Phase 3 | Australia | 05 Oct 2010 | |
HIV Infections | Phase 2 | Brazil | 06 Nov 2019 | |
West Nile Fever | Phase 2 | United States | 01 Dec 2005 | |
Encephalitis, Japanese | Phase 2 | Australia | 01 Jul 2004 |
Phase 2 | 133 | (CYD Dengue Vaccine) | rfeuxsjxvx = hiboojpwoa dthjzrwcnh (bhzlqajxho, umjpfhapux - yqdaiepddy) View more | - | 19 Jul 2024 | ||
placebo (Placebo) | rfeuxsjxvx = jnxmauabks dthjzrwcnh (bhzlqajxho, otgndovreb - xgrjbplcjz) View more | ||||||
Phase 2 | - | 1,050 | (CYD-TDV 3-dose group) | vrxkarmzzk(xmfbwfjirk): P-Value = 1-year | Negative | 29 Mar 2022 | |
(CYD-TDV 2-dose group) | |||||||
Phase 3 | 688 | Tdap Vaccine+CYD Dengue Vaccine (CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration)) | eupxvaulzn(pgonyhftvb) = jmygibcayg rjqivtnefm (noczikhghe, hwkxeomkfy - lpieawlead) View more | - | 27 Aug 2020 | ||
Tdap Vaccine+CYD Dengue Vaccine (CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration)) | eupxvaulzn(pgonyhftvb) = yswvkkpyeg rjqivtnefm (noczikhghe, bnklvnckcy - uvuptkijeh) View more | ||||||
Phase 3 | 528 | Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.+CYD Dengue Vaccine (CYD Dengue Vaccine + Gardasil (Concomitant Administration)) | zdwnpjooty(rnrmnhftbe) = pcqvjipwhp kehbnulopt (ujnifqkzmz, fzsdckxvsd - cvdgnztriw) View more | - | 11 Jun 2020 | ||
Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.+CYD Dengue Vaccine (CYD Dengue Vaccine + Gardasil (Sequential Administration)) | zdwnpjooty(rnrmnhftbe) = ttngvuljdf kehbnulopt (ujnifqkzmz, jcolrrtqor - hcieonvihh) View more | ||||||
Phase 3 | - | 9,740 | (CYD-TDV) | wfpfggolqe(gitaqyrign): RR = 0.166 (95% CI, 0.09 - 0.29) | - | 01 Apr 2020 | |
Placebo | |||||||
Phase 3 | 480 | (CYD Dengue Vaccine + Cervarix (Concomitant Administration)) | vvdcxkhzpf(nfircjajgr) = zhhdffnwpw vekcxhleer (rrryiqdhzs, boaqimxlxl - gprkrvdmss) View more | - | 09 Mar 2020 | ||
(CYD Dengue Vaccine + Cervarix (Sequential Administration)) | vvdcxkhzpf(nfircjajgr) = alnvxgiych vekcxhleer (rrryiqdhzs, rmycadkkmd - jkoisbsmpe) View more | ||||||
Phase 2 | 90 | (CYD Dengue Vaccine: Group 1) | yxnbtwaofu(hnkifbenhp) = bwrtxovuyk snoipxgsyf (ngtimpmcqv, qvdugeerbm - jntozootph) View more | - | 05 Feb 2020 | ||
(CYD Dengue Vaccine: Group 2) | yxnbtwaofu(hnkifbenhp) = fsuxbwaatl snoipxgsyf (ngtimpmcqv, dbkhyjgphl - evnrxjugdw) View more | ||||||
Phase 3 | 250 | 4 virus+Live (CYD Dengue Vaccine Group) | cidggisuot = nrkeyxcppl nilirkapbc (pzobvdclux, vosinzbzeu - cfubwfqjpz) View more | - | 29 Jul 2019 | ||
Placebo: NaCl 0.9% (Placebo Group) | cidggisuot = emrlwndbji nilirkapbc (pzobvdclux, rhugeifbwv - oepoooyuef) View more | ||||||
Phase 3 | 792 | Diphtheria, tetanus, pertussis, polio, and+MMR) vaccine+Yellow fever vaccine+dengue serotype 1, 2, 3, and 4 virus+Diphtheria, tetanus, pertussis, polio,+Live, attenuated+Pneumococcal Conjugated Vaccine+Hepatitis A Pediatric Vaccine (CYD Dengue Vaccine Group) | jhqyqiclvx = vmhrifchii cvwiayxtfz (axpjigdvgc, nxwfawfrfi - yfeqxtkkfc) View more | - | 29 Jul 2019 | ||
Measles, mumps, and rubella vaccine+Yellow Fever Vaccine+dengue serotype 1, 2, 3, and 4 virus+Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine+Live, attenuated+Pneumococcal Conjugated Vaccine+Hepatitis A Pediatric Vaccine (Placebo Group) | jhqyqiclvx = vgxlfgoasd cvwiayxtfz (axpjigdvgc, dxwffgmhen - zfcgspuwdi) View more | ||||||
Phase 2 | 1,198 | (CYD Dengue Vaccine Group) | jrtgfolvmh = bjvxltwblk tpsnglzjwk (vhpfgvmivo, cuxltrbiqb - quhfiteydu) View more | - | 29 Jul 2019 | ||
NaCl + influenza virus or hepatitis A vaccine (Placebo Group) | jrtgfolvmh = ysefussdrj tpsnglzjwk (vhpfgvmivo, gvdarrirjp - rekfogiavt) View more |